Humana Inc. $HUM Shares Sold by Praxis Investment Management Inc.

Praxis Investment Management Inc. cut its holdings in Humana Inc. (NYSE:HUM) by 13.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,700 shares of the insurance provider’s stock after selling 570 shares during the period. Praxis Investment Management Inc.’s holdings in Humana were worth $905,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Cary Street Partners Investment Advisory LLC boosted its holdings in shares of Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after buying an additional 46 shares during the period. Applied Finance Capital Management LLC boosted its holdings in shares of Humana by 1.7% in the 1st quarter. Applied Finance Capital Management LLC now owns 2,943 shares of the insurance provider’s stock valued at $779,000 after buying an additional 48 shares during the period. Blue Trust Inc. boosted its holdings in shares of Humana by 3.6% in the 2nd quarter. Blue Trust Inc. now owns 1,367 shares of the insurance provider’s stock valued at $334,000 after buying an additional 48 shares during the period. Achmea Investment Management B.V. boosted its holdings in shares of Humana by 0.5% in the 1st quarter. Achmea Investment Management B.V. now owns 10,379 shares of the insurance provider’s stock valued at $2,746,000 after buying an additional 49 shares during the period. Finally, Beech Hill Advisors Inc. boosted its holdings in shares of Humana by 6.1% in the 1st quarter. Beech Hill Advisors Inc. now owns 865 shares of the insurance provider’s stock valued at $229,000 after buying an additional 50 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Trading Up 2.9%

Shares of NYSE:HUM opened at $275.00 on Friday. The company has a 50 day moving average of $280.54 and a 200-day moving average of $258.23. The firm has a market cap of $33.07 billion, a P/E ratio of 21.11, a P/E/G ratio of 1.56 and a beta of 0.42. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $315.35. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The company’s revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the company posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, September 26th. Humana’s dividend payout ratio is currently 27.17%.

Analyst Ratings Changes

Several research firms have recently commented on HUM. Wells Fargo & Company lifted their price target on shares of Humana from $344.00 to $347.00 and gave the company an “overweight” rating in a report on Tuesday, October 7th. Bank of America boosted their target price on shares of Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a research note on Friday, October 10th. Barclays reduced their target price on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a research note on Friday, October 3rd. The Goldman Sachs Group started coverage on shares of Humana in a research note on Tuesday. They set a “sell” rating and a $235.00 target price for the company. Finally, Sanford C. Bernstein boosted their target price on shares of Humana from $269.00 to $341.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $297.58.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.